In this regard, in PC-3 prostate cancer cells, IGF-1R signaling has been shown to be attenuated by rosiglitazone via non-genomic action on ERK 1/2, and protein kinase AKT phosphorylation [73]. Here, IGF1R is linked to prostate cancer.